SAGE Therapeutics announces FDA approved drug for HD cognitive therapy

SAGE therapeutics is a biopharmaceutical company with the mission of improving brain health. On 11/13/23, SAGE announcted that the US Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to SAGE-718 for the treatment of Huntington's disease (HD). SAGE-718 is an oral therapy that targets NMDA receptor dysfunction related to cognitive impairment.

Read the article here:

Categories: Uncategorized